{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:00:11Z","timestamp":1791910811319,"version":"4.3.4"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"National Key Research and Development Plan","award":["2022YFC3501304"],"award-info":[{"award-number":["2022YFC3501304"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82071410 and 8210052671"],"award-info":[{"award-number":["No. 82071410 and 8210052671"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The efficacy of efgartigimod in treating myasthenia gravis (MG) patients with muscle-specific kinase (MuSK) antibodies has not been demonstrated in the clinical trial, existing case reports, or observational studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of efgartigimod combined with immunotherapies such as tacrolimus or B-cell depleting agents, as maintenance treatment for MuSK-MG patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This retrospective study included 14 MuSK-MG patients treated with efgartigimod at three tertiary hospitals from 2023 to 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data on the activities of daily living (ADL) scores, Quantitative Myasthenia Gravis scores, and the time reaching minimal symptom expression (MSE) were collected. The combined use of steroids, immunosuppressants, and rescue therapies, as well as the adverse event incidence, were also recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean age at first efgartigimod treatment was 55\u2009\u00b1\u200918\u2009years old with a median follow-up time of 28\u2009weeks. From baseline to week 4, MG-ADL scores decreased significantly from 10.1\u2009\u00b1\u20094.0 to 2.2\u2009\u00b1\u20093.1 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200914,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.001). The majority of patients (92.9%) maintains a reduction of at least 2\u2009points for more than 8\u2009weeks. The median time to achieve MSE was 4\u2009weeks, with 71.4% (10\/14) of patients reaching MSE by week 12. In patients receiving CD20 B cell depleting therapy or tacrolimus as maintenance, the time-weighted average dosage of prednisone was 16\u2009mg while that in those with prednisone alone was 37\u2009mg. Of all the 14 patients, one developed an upper respiratory tract infection 4\u2009weeks after rituximab (RTX), and one was infected with herpes zoster virus 13\u2009weeks after RTX.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>A single-cycle efgartigimod as an induction therapy, combined with immunotherapies such as tacrolimus or B cell depleting agents, as maintenance treatment, could benefit MuSK-MG patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864251326778","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T01:29:56Z","timestamp":1742606996000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Efgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5029-290X","authenticated-orcid":false,"given":"Yufan","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"National Center for Neurological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoxian","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Neurology, Qilu Hospital (Qingdao), Shandong University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9033-7568","authenticated-orcid":false,"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"National Center for Neurological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5298-3993","authenticated-orcid":false,"given":"Jie","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"National Center for Neurological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"National Center for Neurological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9955-7179","authenticated-orcid":false,"given":"Dingxian","family":"He","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"National Center for Neurological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"National Center for Neurological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"National Center for Neurological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9481-1418","authenticated-orcid":false,"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"National Center for Neurological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-2544","authenticated-orcid":false,"given":"Huan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-3431","authenticated-orcid":false,"given":"Qinzhou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Qilu Hospital, Shandong University, 107 Wenhua Xilu, Jinan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai 200040, China"},{"name":"Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"National Center for Neurological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06781.x"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-016-0668-z"},{"key":"e_1_3_5_4_2","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh J","year":"2013","unstructured":"Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med 2013; 86: 255\u2013260.","journal-title":"Yale J Biol Med"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1313944110"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-302705"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000228225.23349.5d"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00613"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241273036"},{"key":"e_1_3_5_10_2","unstructured":"Rozanolixizumab-noli [package insert].Brussels Belgium: UCB Pharma https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761286s000lbl.pdf (2023 accessed 30 November 2024)."},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1401972"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16189"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200276"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52142"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94263"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.01.013"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830220939"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12588-7"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.933296"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.877895"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01210-1"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001116"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004341"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27233"},{"key":"e_1_3_5_31_2","unstructured":"Efgartigimod alfa-fcab [package insert].Amsterdam Netherlands: Argenx BV https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761195s004 761304s003lbl.pdf (2024 accessed 30 November 2024)."},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.05.021"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251326778","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251326778","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251326778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:04:59Z","timestamp":1767675899000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251326778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":31,"alternative-id":["10.1177\/17562864251326778"],"URL":"https:\/\/doi.org\/10.1177\/17562864251326778","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"17562864251326778"}}